Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1E | P28566 | 3/20 | 0.69 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.55 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049447 | 0.98 | HTR1E (0.71) | HTR1ES1PR3MEN1LMNAKMT2A | |
| SCHEMBL13923636 | 0.83 | HTR1E (0.74) | HTR1ES1PR3MEN1LMNAKMT2A | |
| SCHEMBL12531975 | 0.82 | HTR1E (0.63) | HTR1ES1PR3MEN1LMNAKMT2A | |
| SCHEMBL193456 | 0.82 | HTR1E (0.63) | HTR1ES1PR3MEN1LMNAKMT2A | |
| SCHEMBL67219 | 0.82 | HTR1E (0.63) | HTR1ES1PR3MEN1LMNAKMT2A | |
| SCHEMBL5746887 | 0.82 | HTR1E (0.63) | HTR1ES1PR3MEN1LMNAKMT2A | |
| SCHEMBL5049482 | 0.81 | CYP1A2 (0.63) | HTR1ES1PR3MEN1LMNAKMT2A | |
| SCHEMBL9780781 | 0.81 | HTR1E (0.61) | HTR1ES1PR3MEN1LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL11526873 | 0.81 | HTR1E (0.61) | HTR1ES1PR3MEN1LMNAKMT2A | |
| SCHEMBL28622389 | 0.80 | HTR1E (0.65) | HTR1ES1PR3MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679220-A | Histone deacetylase inhibitor | METHYLGENE INC | 2010-03-24 | — | — | CN | claimed |
| EP-2139850-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2010-01-06 | — | — | EP | claimed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | claimed |
| WO-2008122115-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-10-16 | — | — | WO | claimed |
| EP-1948164-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-07-30 | — | — | EP | claimed |
| WO-2007045979-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | claimed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| CN-101679220-A | Histone deacetylase inhibitor | METHYLGENE INC | 2010-03-24 | — | — | CN | disclosed |
| EP-2139850-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2010-01-06 | — | — | EP | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| WO-2008122115-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122115-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | HTR1E 1108/4885S1PR3 2981/4885MEN1 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.